Biomarkers in prostate cancer: Insights from discovery to clinical application

Dr. Nallasivam Palanisamy (Associate Scientist, Department of Urology, Henry Ford Health and Associate Professor of Research, Michigan State University) explores how next-generation sequencing (NGS) is transforming prostate cancer care. He highlights the discovery of RAF kinase and pseudogene-related gene fusions, and explains how NGS enables precise detection of complex genetic changes. These insights are helping guide clinical decisions, from risk assessment to personalized treatment, by accounting for tumor heterogeneity and the interplay of genetic, epigenetic, and environmental factors.